Hemorrhagic cystitis in patients treated with cabazitaxel: a radiation recall syndrome?

Grellety, Thomas; Houédé, Nadine; Hoepffner, J.; Riviere, J.; C, Merino; Lieutenant, Vincent; Gross‐Goupil, Marine; Richaud, Pierre; Dupin, Charles; Sargos, P.; Roubaud, Guilhem

doi:10.1093/annonc/mdu132

Cited by 13 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 In patients who were treated with cabazitaxel in the TROPIC study, 17% had hematuria of all grades. 13 Grellety et al reported on four patients who had cabazitaxel-induced hematuria and cystitis, and after finding all four patients had a history of pelvic radiation, 2 they suggested the patients’ hematuria and cystitis could be attributed to a radiation recall syndrome. However, Kosaka and Oya reported a patient who developed hemorrhagic cystitis after cabazitaxel treatment for CRPC, and this patient had not received pelvic radiation therapy.…”

Section: Discussionmentioning

confidence: 99%

“…1 Bladder wall enhancement and ureteral enhancement have been observed anecdotally in patients being treated with this agent and are thought to be related to cystitis and ureteritis. 2 Interstitial cystitis has also been reported in patients receiving other taxanes 3 ; however, the incidence and clinical significance of these findings have not been established.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without Carboplatin

Bilen

Cauley

Atkinson

et al. 2017

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

Introduction Although myeloid growth factors are commonly used to treat metastatic castration-resistant prostate cancer (mCRPC), the optimal timing of administration has not been well studied. We assessed the effects of same-day pegfilgrastim, a neutrophil stimulator, after cabazitaxel treatment with or without carboplatin in patients with mCRPC. We also evaluated the frequency of urinary tract inflammation during treatment. Patients and Methods Between September 2010 and September 2014, 151 consecutive patients with mCRPC underwent cabazitaxel treatment with or without the addition of carboplatin at a single institution. We assessed absolute neutrophil count recovery, incidence of neutropenia, neutropenic fever, antibiotic usage, treatment delays or discontinuation, dose reduction, and hospitalization with pegfilgrastim administration. Radiologists blinded to therapy reviewed CT scans to detect urinary tract inflammation. Results The median patient age was 69 years (range, 41–88 years), 78% were white, and 54% had a Gleason score ≥9. Median overall survival was 9 months (95% confidence interval, 8–11). One patient (<1%) had neutropenia; 38 patients (25%) had infection. During cycle 1, a significantly higher proportion of patients receiving pegfilgrastim after 24 hours developed infection than did those receiving pegfilgrastim the same day (26% vs. 6%, P = 0.01). Conclusion Same-day pegfilgrastim administration after cabazitaxel treatment with or without carboplatin in patients with mCRPC is feasible. The urinary tract inflammation rate (21%) was higher than that reported anecdotally. Results need to be prospectively validated.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without Carboplatin

Bilen

Cauley

Atkinson

et al. 2017

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

show abstract

“…There is at least one case series we are aware of that has histologically shown urothelial inflammation from Cabazitaxel induced radiation recall syndrome [8]. Whilst our case series exhibits some atypical features we feel the most likely cause for these inflammatory change is a radiation recall syndrome.…”

Section: Discussionmentioning

confidence: 72%

CT findings in patients with Cabazitaxel induced pelvic pain and haematuria: a case series

2017

View full text Add to dashboard Cite

BackgroundHaematuria and pelvic pain are recognized and documented adverse reactions related to Cabazitaxel use. To date there has not been any documentation of imaging findings in patients with this presentation.CasesWe report a case series of five patients who experienced these symptoms while on Cabazitaxel and were all found to have very similar urothelial changes on CT. The patients were noted to have ureteric and renal pelvic dilatation along with urothelial enhancement (in those who had post contrast imaging). All of these changes were noted to be reversible in those who had follow up imaging after cessation of Cabazitaxel and initiation of a short course of steroids.ConclusionThis case series helps demonstrate the pathological reversible urothelial inflammatory changes that may be occurring in patients experiencing haematuria and pelvic pain on Cabazitaxel therapy. These changes may relate to direct toxic effect of drug metabolites, a radiation recall type phenomenon or a combination of both.

show abstract

“…Case reports of hemorrhagic cystitis, which may be due to radiation recall in patients with history of pelvic irradiation. High rates of grade 3/4 neutropenia in clinical trials [97,141,213] 28 RPLS has occurred rarely in trials. Monitor for headache, seizure, lethargy, and hypertension.…”

Section: Toxicities Of Anticancer Therapymentioning

confidence: 99%

Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit

Rivera

Bryan

et al. 2018

Oncologic Critical Care

View full text Add to dashboard Cite

Advances in the management of hematologic malignancies and solid tumors have given rise to diverse modalities to treat cancer other than cytotoxic chemotherapy, including targeted therapies, immunotherapies, and cellular therapies.Currently, there are over 175 FDA-approved antineoplastic agents in the United States, many with a diverse and profound toxicity profile. Complications of antineoplastic therapy may result in the need for intensive care unit (ICU) admission to provide acute symptom management. Accordingly, ICU providers caring for cancer patients should have a working knowledge of the toxicities and complications associated with antineoplastic therapy.

show abstract

Hemorrhagic cystitis in patients treated with cabazitaxel: a radiation recall syndrome?

Cited by 13 publications

References 5 publications

Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without Carboplatin

Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without Carboplatin

CT findings in patients with Cabazitaxel induced pelvic pain and haematuria: a case series

Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit

Contact Info

Product

Resources

About